LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

COMPASS Pathways plc (CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Investing.com - Oppenheimer 已将 Compass Pathways (NASDAQ:CMPS) 的评级从"中性"上调至"跑赢大盘"，并设定 $15.00 的目标价，看好其用于治疗难治性抑郁症的裸盖菇素疗法的潜力。该目标价较当前 $6.37 的股价有显著上涨空间，而该股票在过去一周已经取得了惊人的 27.53% 涨幅。

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731175223/en/ The articles, information, and content displayed on this webpage ...

Analysts are expecting Compass Pathways' stock to blast off soon. There aren't actually any expected near-term events which might drive such a rise. It's fully believable that the company will become ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who ...